1
|
Arrabal-Gómez C, Serrano-Castro P, Sánchez-Pérez JA, Garcia-Casares N, Fuxe K, Borroto-Escuela D, Narváez M. Potentiation of antidepressant effects: NPY1R agonist and ketamine synergy enhances TrkB signaling and neurogenesis in the ventral hippocampus. Expert Opin Ther Targets 2024:1-14. [PMID: 38626283 DOI: 10.1080/14728222.2024.2342524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2024] [Accepted: 04/05/2024] [Indexed: 04/18/2024]
Abstract
BACKGROUND Major Depressive Disorder (MDD) poses a significant challenge to global health, with current treatments often limited by efficacy and onset delays. This study explores the synergistic antidepressant-like effects of an NPY1R agonist and Ketamine, targeting their neurobiological interactions within the ventral hippocampus. RESEARCH DESIGN AND METHODS Utilizing a preclinical model, this study administered Neuropeptide Y receptor 1 (NPY1R) agonist and Ketamine, both separately and in combination, through intracerebroventricular (icv) and intranasal (i.n.) routes. The Forced Swimming Test (FST) was employed to assess antidepressant-like activity, while in situ Proximity Ligation Assay and immunohistochemistry were used to examine NPY1R/TrkB heteroreceptor complexes and BDNF expression in the ventral dentate gyrus (DG), along with neurogenesis markers. RESULTS The combined treatment significantly reduced immobility in the FST, indicative of enhanced antidepressant-like effects, correlated with increased formation of NPY1R/TrkB complex and brain-derived neurotrophic factor (BDNF) expression in the ventral DG. These molecular alterations were associated with increased neurogenesis. CONCLUSIONS The coadministration of an NPY1R agonist and Ketamine in a rodent model demonstrated potentiated antidepressant responses through synergistic neurobiological pathways, including TrkB signaling and hippocampal neurogenesis. This indicates a novel therapeutic strategy for MDD, warranting further clinical investigation to fully understand its implications.
Collapse
Affiliation(s)
- Carlos Arrabal-Gómez
- Instituto de Investigación Biomédica de Málaga, NeuronLab, Facultad de Medicina, Universidad de Málaga, Málaga, Spain
- Instituto de Investigación Biomédica de Málaga, Unit of Neurology, Hospital Regional Universitario de Málaga, Málaga, Spain
- Vithas Málaga, Grupo Hospitalario Vithas, Málaga, Spain
- Instituto de Investigación Biomédica de Málaga, Facultad de Psicología, Universidad de Málaga, Málaga, Spain
| | - Pedro Serrano-Castro
- Instituto de Investigación Biomédica de Málaga, NeuronLab, Facultad de Medicina, Universidad de Málaga, Málaga, Spain
- Instituto de Investigación Biomédica de Málaga, Unit of Neurology, Hospital Regional Universitario de Málaga, Málaga, Spain
- Vithas Málaga, Grupo Hospitalario Vithas, Málaga, Spain
| | - Jose Andrés Sánchez-Pérez
- Instituto de Investigación Biomédica de Málaga, NeuronLab, Facultad de Medicina, Universidad de Málaga, Málaga, Spain
- Instituto de Investigación Biomédica de Málaga, Unit of Psychiatry, Hospital Universitario Virgen de la Victoria, Malaga, Spain
| | - Natalia Garcia-Casares
- Instituto de Investigación Biomédica de Málaga, NeuronLab, Facultad de Medicina, Universidad de Málaga, Málaga, Spain
| | - Kjell Fuxe
- Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | - Dasiel Borroto-Escuela
- Instituto de Investigación Biomédica de Málaga, NeuronLab, Facultad de Medicina, Universidad de Málaga, Málaga, Spain
- Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
- Receptomics and Brain disorders lab, Edificio Lopez-Peñalver, Instituto de Investigación Biomédica de Málaga, Facultad de Medicina, Universidad de Málaga, Málaga, Spain
| | - Manuel Narváez
- Instituto de Investigación Biomédica de Málaga, NeuronLab, Facultad de Medicina, Universidad de Málaga, Málaga, Spain
- Instituto de Investigación Biomédica de Málaga, Unit of Neurology, Hospital Regional Universitario de Málaga, Málaga, Spain
- Vithas Málaga, Grupo Hospitalario Vithas, Málaga, Spain
| |
Collapse
|
2
|
Arrabal-Gómez C, Beltran-Casanueva R, Hernández-García A, Bayolo-Guanche JV, Barbancho-Fernández MA, Serrano-Castro PJ, Narváez M. Enhancing Cognitive Functions and Neuronal Growth through NPY1R Agonist and Ketamine Co-Administration: Evidence for NPY1R-TrkB Heteroreceptor Complexes in Rats. Cells 2024; 13:669. [PMID: 38667284 PMCID: PMC11049095 DOI: 10.3390/cells13080669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2024] [Revised: 04/03/2024] [Accepted: 04/10/2024] [Indexed: 04/28/2024] Open
Abstract
This study investigates the combined effects of the neuropeptide Y Y1 receptor (NPY1R) agonist [Leu31-Pro34]NPY at a dose of 132 µg and Ketamine at 10 mg/Kg on cognitive functions and neuronal proliferation, against a backdrop where neurodegenerative diseases present an escalating challenge to global health systems. Utilizing male Sprague-Dawley rats in a physiological model, this research employed a single-dose administration of these compounds and assessed their impact 24 h after treatment on object-in-place memory tasks, alongside cellular proliferation within the dorsal hippocampus dentate gyrus. Methods such as the in situ proximity ligation assay and immunohistochemistry for proliferating a cell nuclear antigen (PCNA) and doublecortin (DCX) were utilized. The results demonstrated that co-administration significantly enhanced memory consolidation and increased neuronal proliferation, specifically neuroblasts, without affecting quiescent neural progenitors and astrocytes. These effects were mediated by the potential formation of NPY1R-TrkB heteroreceptor complexes, as suggested by receptor co-localization studies, although further investigation is required to conclusively prove this interaction. The findings also highlighted the pivotal role of brain-derived neurotrophic factor (BDNF) in mediating these effects. In conclusion, this study presents a promising avenue for enhancing cognitive functions and neuronal proliferation through the synergistic action of the NPY1R agonist and Ketamine, potentially via NPY1R-TrkB heteroreceptor complex formation, offering new insights into therapeutic strategies for neurodegenerative diseases.
Collapse
Affiliation(s)
- Carlos Arrabal-Gómez
- NeuronLab, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, 29071 Málaga, Spain; (C.A.-G.); (M.A.B.-F.)
- Facultad de Psicología, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, 29071 Málaga, Spain
- Unit of Neurology, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, 29010 Málaga, Spain
- Vithas Málaga, Grupo Hospitalario Vithas, 29016 Málaga, Spain
| | - Rasiel Beltran-Casanueva
- Department of Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden; (R.B.-C.); (A.H.-G.); (J.V.B.-G.)
- Receptomics and Brain Disorders Lab, Edificio Lopez-Peñalver, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, 29071 Málaga, Spain
| | - Aracelis Hernández-García
- Department of Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden; (R.B.-C.); (A.H.-G.); (J.V.B.-G.)
- Receptomics and Brain Disorders Lab, Edificio Lopez-Peñalver, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, 29071 Málaga, Spain
| | - Juan Vicente Bayolo-Guanche
- Department of Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden; (R.B.-C.); (A.H.-G.); (J.V.B.-G.)
- Receptomics and Brain Disorders Lab, Edificio Lopez-Peñalver, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, 29071 Málaga, Spain
| | - Miguel Angel Barbancho-Fernández
- NeuronLab, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, 29071 Málaga, Spain; (C.A.-G.); (M.A.B.-F.)
| | - Pedro Jesús Serrano-Castro
- NeuronLab, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, 29071 Málaga, Spain; (C.A.-G.); (M.A.B.-F.)
- Unit of Neurology, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, 29010 Málaga, Spain
- Vithas Málaga, Grupo Hospitalario Vithas, 29016 Málaga, Spain
| | - Manuel Narváez
- NeuronLab, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga, Universidad de Málaga, 29071 Málaga, Spain; (C.A.-G.); (M.A.B.-F.)
- Unit of Neurology, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, 29010 Málaga, Spain
- Vithas Málaga, Grupo Hospitalario Vithas, 29016 Málaga, Spain
| |
Collapse
|
3
|
Higueras Y, Borges M, Jiménez-Martín I, Conde C, Aparicio-Mingueza A, Sierra-Martínez E, Gich-Fulla J, Balaguer-Marmaña M, Gil-Sánchez A, Anglada E, Jover A, Pérez-Martín MY, Arévalo MJ, Arrabal-Gómez C, Jiménez-Veiga J, Lubrini G, Molano A, García-Vaz F. Cognitive assessment in patients with multiple sclerosis: A Spanish consensus. Front Rehabil Sci 2022; 3:1006699. [PMID: 36605095 PMCID: PMC9810074 DOI: 10.3389/fresc.2022.1006699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Accepted: 11/01/2022] [Indexed: 12/24/2022]
Affiliation(s)
- Yolanda Higueras
- Department of Neurology, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain,Department of Cognitive Processes and Speech Therapy, School of Psychology, Experimental Psychology, Complutense University, Madrid, Spain,Correspondence: Yolanda Higueras
| | - Mónica Borges
- Department of Neurology, Virgen Macarena Hospital, Seville, Spain
| | - Isabel Jiménez-Martín
- Department of Neurology, Health Research Institute Foundation of Santiago de Compostela (FIDIS), University Clinical Hospital from Santiago de Compostela, Santiago de Compostela, Spain
| | - Cristina Conde
- Neurology Service, Maimonides Institute for Research in Biomedicine of Cordoba, (IMIBIC), Reina Sofía University Hospital, Cordoba, Spain
| | | | - Esther Sierra-Martínez
- Department of Neurorehabilitation, Hospital San Juan de Dios, Zaragoza, Spain,Fundación Neurópolis, Zaragoza, Spain
| | - Jordi Gich-Fulla
- Department of Neurology, Dr. Josep Trueta University Hospital, Girona, Spain
| | - Marta Balaguer-Marmaña
- Department of Neurology, Consorci Sanitari Integral Moisés Broggi Hospital, Sant Joan Despí, Spain
| | - Anna Gil-Sánchez
- Department of Neuroimmunology, Biomedicine Research Institute of Lleida, Lleida, Spain
| | - Elisenda Anglada
- Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Ana Jover
- Neurology Service, Maimonides Institute for Research in Biomedicine of Cordoba, (IMIBIC), Reina Sofía University Hospital, Cordoba, Spain
| | | | - María Jesús Arévalo
- Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Hospital Universitari Vall d'Hebron, Barcelona, Spain
| | - Carlos Arrabal-Gómez
- Department of Psychobiology and Methodology of Behavioral Sciences, University of Málaga, Málaga, Spain
| | - Judith Jiménez-Veiga
- Department of Neurology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
| | - Genny Lubrini
- Department of Cognitive Processes and Speech Therapy, School of Psychology, Experimental Psychology, Complutense University, Madrid, Spain
| | - Ana Molano
- Department of Neurology, Hospital de Cruces, Bilbao, Spain
| | - Fabiola García-Vaz
- Department of Cognitive Processes and Speech Therapy, School of Psychology, Experimental Psychology, Complutense University, Madrid, Spain,Multiple Sclerosis Fundation, Madrid, Spain
| |
Collapse
|
4
|
Serrano-Castro PJ, Estivill-Torrús G, Cabezudo-García P, Reyes-Bueno JA, Ciano Petersen N, Aguilar-Castillo MJ, Suárez-Pérez J, Jiménez-Hernández MD, Moya-Molina MÁ, Oliver-Martos B, Arrabal-Gómez C, Rodríguez de Fonseca F. Impact of SARS-CoV-2 infection on neurodegenerative and neuropsychiatric diseases: a delayed pandemic? Neurologia 2020; 35:245-251. [PMID: 32364119 PMCID: PMC7164900 DOI: 10.1016/j.nrl.2020.04.002] [Citation(s) in RCA: 94] [Impact Index Per Article: 23.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Accepted: 04/14/2020] [Indexed: 02/08/2023] Open
Abstract
INTRODUCTION SARS-CoV-2 was first detected in December 2019 in the Chinese city of Wuhan and has since spread across the world. At present, the virus has infected over 1.7 million people and caused over 100 000 deaths worldwide. Research is currently focused on understanding the acute infection and developing effective treatment strategies. In view of the magnitude of the epidemic, we conducted a speculative review of possible medium- and long-term neurological consequences of SARS-CoV-2 infection, with particular emphasis on neurodegenerative and neuropsychiatric diseases of neuroinflammatory origin, based on the available evidence on neurological symptoms of acute SARS-CoV-2 infection. DEVELOPMENT We systematically reviewed the available evidence about the pathogenic mechanisms of SARS-CoV-2 infection, the immediate and lasting effects of the cytokine storm on the central nervous system, and the consequences of neuroinflammation for the central nervous system. CONCLUSIONS SARS-CoV-2 is a neuroinvasive virus capable of triggering a cytokine storm, with persistent effects in specific populations. Although our hypothesis is highly speculative, the impact of SARS-CoV-2 infection on the onset and progression of neurodegenerative and neuropsychiatric diseases of neuroinflammatory origin should be regarded as the potential cause of a delayed pandemic that may have a major public health impact in the medium to long term. Cognitive and neuropsychological function should be closely monitored in COVID-19 survivors.
Collapse
Affiliation(s)
- P J Serrano-Castro
- Servicio de Neurología, Hospital Regional Universitario de Málaga, Málaga, España; Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; Red Andaluza de Investigación Clínica y Traslacional en Neurología (Neuro-RECA).
| | - G Estivill-Torrús
- Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; Red Andaluza de Investigación Clínica y Traslacional en Neurología (Neuro-RECA)
| | - P Cabezudo-García
- Servicio de Neurología, Hospital Regional Universitario de Málaga, Málaga, España; Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; Red Andaluza de Investigación Clínica y Traslacional en Neurología (Neuro-RECA)
| | - J A Reyes-Bueno
- Servicio de Neurología, Hospital Regional Universitario de Málaga, Málaga, España; Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; Red Andaluza de Investigación Clínica y Traslacional en Neurología (Neuro-RECA)
| | - N Ciano Petersen
- Servicio de Neurología, Hospital Regional Universitario de Málaga, Málaga, España; Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; Red Andaluza de Investigación Clínica y Traslacional en Neurología (Neuro-RECA)
| | - M J Aguilar-Castillo
- Red Andaluza de Investigación Clínica y Traslacional en Neurología (Neuro-RECA); Servicio de Análisis Clínicos, Hospital Regional Universitario de Málaga, Málaga, España
| | - J Suárez-Pérez
- Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; Red Andaluza de Investigación Clínica y Traslacional en Neurología (Neuro-RECA)
| | - M D Jiménez-Hernández
- Red Andaluza de Investigación Clínica y Traslacional en Neurología (Neuro-RECA); Servicio de Neurología, Hospital Universitario Virgen del Rocío, Sevilla, España
| | - M Á Moya-Molina
- Red Andaluza de Investigación Clínica y Traslacional en Neurología (Neuro-RECA); Servicio de Neurología, Hospital Universitario Puerta del Mar, Cádiz, España
| | - B Oliver-Martos
- Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; Red Andaluza de Investigación Clínica y Traslacional en Neurología (Neuro-RECA)
| | - C Arrabal-Gómez
- Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; Red Andaluza de Investigación Clínica y Traslacional en Neurología (Neuro-RECA)
| | - F Rodríguez de Fonseca
- Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, España; Red Andaluza de Investigación Clínica y Traslacional en Neurología (Neuro-RECA)
| |
Collapse
|